Centessa Pharmaceuticals (CNTA) EBT Margin (2025)

Centessa Pharmaceuticals (CNTA) reported EBT Margin of 164.92% for Q1 2025.

Centessa Pharmaceuticals (CNTA) EBT Margin (2025) Analysis & Trends

Centessa Pharmaceuticals (CNTA) has 1 years of EBT Margin data on file, last reported at 164.92% in Q1 2025.

  • EBT Margin for Q1 2025 came in at 164.92%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 1304.75% (changed N/A YoY), and the FY2025 annual result was 1304.75%, changed N/A from the prior year.
  • EBT Margin steadied at 164.92% in Q1 2025 per CNTA's latest filing.
  • Over five years, EBT Margin peaked at 164.92% in Q1 2025 and troughed at 164.92% in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 6.40%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 41.95%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Centessa Pharmaceuticals 6.15 Bn 6.15 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2025 -164.92%